Kanagawa, Japan

Masami Hamano

This inventor holds 1 USPTO granted patent. Top assignee: Kyowa Hakko Kogyo Co., Ltd.. Active years: 2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masami Hamano. Retrieved from https://idiyas.com/inventor/masami-hamano-b57mh3w3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masami Hamano: Innovator in Apoptosis Induction

Introduction

Masami Hamano is a notable inventor based in Kanagawa, Japan. She has made significant contributions to the field of medicine, particularly in the development of agents that induce apoptosis. Her work is crucial in the fight against diseases such as cancer and AIDS.

Latest Patents

Masami Hamano holds a patent for an "Agent for inducing apoptosis." This patent involves agents comprising a tetrocarcin derivative, which serves as an active ingredient. These agents are designed to be effective as medicaments for the preventive and therapeutic treatment of diseases associated with increased expression of Bcl-2 family proteins.

Career Highlights

Hamano is associated with Kyowa Hakko Kogyo Co., Ltd., where she continues to innovate in her field. Her research focuses on developing therapeutic agents that can combat serious health issues.

Collaborations

Some of her notable coworkers include Mitsunobu Hara and Yutaka Kanda, who contribute to her research endeavors.

Conclusion

Masami Hamano's work in apoptosis induction represents a significant advancement in medical science, showcasing her dedication to improving health outcomes through innovative research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…